These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 29198116)

  • 1. Characterization and Detection of Erythropoietin Fc Fusion Proteins Using Liquid Chromatography-Mass Spectrometry.
    Mesonzhnik NV; Postnikov PV; Appolonova SA; Krotov GI
    J Proteome Res; 2018 Jan; 17(1):689-697. PubMed ID: 29198116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fc-fragment removal allows the EPO-Fc fusion protein to be detected in blood samples by IEF-PAGE.
    Postnikov P; Krotov G; Mesonzhnik N; Efimova Y; Rodchenkov G
    Drug Test Anal; 2015; 7(11-12):999-1008. PubMed ID: 26695487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of Western blotting and LC-HRMS.
    Walpurgis K; Thomas A; Vogel M; Reichel C; Geyer H; Schänzer W; Thevis M
    Drug Test Anal; 2016 Nov; 8(11-12):1152-1161. PubMed ID: 27649383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined detection of the ActRII-Fc fusion proteins Sotatercept (ActRIIA-Fc) and Luspatercept (modified ActRIIB-Fc) in serum by means of immunoaffinity purification, tryptic digestion, and LC-MS/MS.
    Walpurgis K; Thomas A; Lange T; Reichel C; Geyer H; Thevis M
    Drug Test Anal; 2018 Nov; 10(11-12):1714-1721. PubMed ID: 30285318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin.
    Im SJ; Yang SI; Yang SH; Choi DH; Choi SY; Kim HS; Jang DS; Jin KS; Chung YK; Kim SH; Paik SH; Park YC; Chung MK; Kim YB; Han KH; Choi KY; Sung YC
    PLoS One; 2011; 6(9):e24574. PubMed ID: 21957455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of EPO-Fc fusion protein in human blood: screening and confirmation protocols for sports drug testing.
    Reichel C; Thevis M
    Drug Test Anal; 2012 Nov; 4(11):818-29. PubMed ID: 22764129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A hingeless Fc fusion system for site-specific cleavage by IdeS.
    Novarra S; Grinberg L; Rickert KW; Barnes A; Wilson S; Baca M
    MAbs; 2016; 8(6):1118-25. PubMed ID: 27210548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Fc glycosylation analysis of Fc fusions with IdeS and liquid chromatography mass spectrometry.
    Lynaugh H; Li H; Gong B
    MAbs; 2013; 5(5):641-5. PubMed ID: 23839239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A universal surrogate peptide to enable LC-MS/MS bioanalysis of a diversity of human monoclonal antibody and human Fc-fusion protein drug candidates in pre-clinical animal studies.
    Furlong MT; Ouyang Z; Wu S; Tamura J; Olah T; Tymiak A; Jemal M
    Biomed Chromatogr; 2012 Aug; 26(8):1024-32. PubMed ID: 22623136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-secretion neutralization of transgene-derived effect: soluble erythropoietin receptor/IgG1Fc expressed in liver neutralizes erythropoietin produced in muscle.
    Maruyama H; Higuchi M; Higuchi N; Kameda S; Saito M; Sugawa M; Matsuzaki J; Neichi T; Yokoyama S; Miyazaki Y; Miyazaki J; Gejyo F
    J Gene Med; 2004 Feb; 6(2):228-37. PubMed ID: 14978776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, characterisation, and mass spectrometric detection of a pegylated EPO-mimetic peptide for sports drug testing purposes.
    Möller I; Thomas A; Geyer H; Schänzer W; Thevis M
    Rapid Commun Mass Spectrom; 2011 Aug; 25(15):2115-23. PubMed ID: 21710591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery, characterization, and remediation of a C-terminal Fc-extension in proteins expressed in CHO cells.
    Spahr CS; Daris ME; Graham KC; Soriano BD; Stevens JL; Shi SD
    MAbs; 2018; 10(8):1291-1300. PubMed ID: 30148415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous Catabolite Identification and Quantitation of Large Therapeutic Protein at the Intact Level by Immunoaffinity Capture Liquid Chromatography-High-Resolution Mass Spectrometry.
    Kang L; Camacho RC; Li W; D'Aquino K; You S; Chuo V; Weng N; Jian W
    Anal Chem; 2017 Jun; 89(11):6065-6075. PubMed ID: 28457123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EPOR-Based Purification and Analysis of Erythropoietin Mimetic Peptides from Human Urine by Cys-Specific Cleavage and LC/MS/MS.
    Vogel M; Thomas A; Schänzer W; Thevis M
    J Am Soc Mass Spectrom; 2015 Sep; 26(9):1617-25. PubMed ID: 26122516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doping control analysis of recombinant human erythropoietin, darbepoetin alfa and methoxy polyethylene glycol-epoetin beta in equine plasma by nano-liquid chromatography-tandem mass spectrometry.
    Yu NH; Ho EN; Wan TS; Wong AS
    Anal Bioanal Chem; 2010 Apr; 396(7):2513-21. PubMed ID: 20148243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-depth site-specific O-Glycosylation analysis of therapeutic Fc-fusion protein by electron-transfer/higher-energy collisional dissociation mass spectrometry.
    Hashii N; Suzuki J; Hanamatsu H; Furukawa JI; Ishii-Watabe A
    Biologicals; 2019 Mar; 58():35-43. PubMed ID: 30704904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiation and identification of recombinant human erythropoietin and darbepoetin Alfa in equine plasma by LC-MS/MS for doping control.
    Guan F; Uboh CE; Soma LR; Birks E; Chen J; You Y; Rudy J; Li X
    Anal Chem; 2008 May; 80(10):3811-7. PubMed ID: 18380469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway.
    Bitonti AJ; Dumont JA; Low SC; Peters RT; Kropp KE; Palombella VJ; Stattel JM; Lu Y; Tan CA; Song JJ; Garcia AM; Simister NE; Spiekermann GM; Lencer WI; Blumberg RS
    Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9763-8. PubMed ID: 15210944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of rhEPO-L-Fc fusion protein and analysis of its bioactivity and pharmacokinetics].
    Zhu Q; Huang Z; Huang Y; Qin Y
    Sheng Wu Gong Cheng Xue Bao; 2008 Nov; 24(11):1874-9. PubMed ID: 19256332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond.
    Way JC; Lauder S; Brunkhorst B; Kong SM; Qi A; Webster G; Campbell I; McKenzie S; Lan Y; Marelli B; Nguyen LA; Degon S; Lo KM; Gillies SD
    Protein Eng Des Sel; 2005 Mar; 18(3):111-8. PubMed ID: 15820978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.